These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23764065)

  • 1. Arrestin pathways as drug targets.
    Luttrell LM
    Prog Mol Biol Transl Sci; 2013; 118():469-97. PubMed ID: 23764065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergent biological properties of arrestin pathway-selective biased agonism.
    Appleton KM; Luttrell LM
    J Recept Signal Transduct Res; 2013 Jun; 33(3):153-61. PubMed ID: 23448506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity.
    Appleton KM; Lee MH; Alele C; Alele C; Luttrell DK; Peterson YK; Morinelli TA; Luttrell LM
    Methods Enzymol; 2013; 522():229-62. PubMed ID: 23374189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.
    Luttrell LM; Maudsley S; Bohn LM
    Mol Pharmacol; 2015 Sep; 88(3):579-88. PubMed ID: 26134495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refining efficacy: exploiting functional selectivity for drug discovery.
    Gesty-Palmer D; Luttrell LM
    Adv Pharmacol; 2011; 62():79-107. PubMed ID: 21907907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-arrestin-biased ligands at seven-transmembrane receptors.
    Violin JD; Lefkowitz RJ
    Trends Pharmacol Sci; 2007 Aug; 28(8):416-22. PubMed ID: 17644195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translating in vitro ligand bias into in vivo efficacy.
    Luttrell LM; Maudsley S; Gesty-Palmer D
    Cell Signal; 2018 Jan; 41():46-55. PubMed ID: 28495495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biased signalling: the instinctive skill of the cell in the selection of appropriate signalling pathways.
    Liu Y; Yang Y; Ward R; An S; Guo XX; Li W; Xu TR
    Biochem J; 2015 Sep; 470(2):155-67. PubMed ID: 26348905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heptahelical terpsichory. Who calls the tune?
    Gesty-Palmer D; Luttrell LM
    J Recept Signal Transduct Res; 2008; 28(1-2):39-58. PubMed ID: 18437629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.
    Luttrell LM
    Mol Endocrinol; 2014 Mar; 28(3):281-94. PubMed ID: 24433041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel roles for arrestins in G protein-coupled receptor biology and drug discovery.
    Claing A; Laporte SA
    Curr Opin Drug Discov Devel; 2005 Sep; 8(5):585-9. PubMed ID: 16159020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo veritas, the next frontier for functionally selective GPCR ligands.
    Beaulieu JM
    Methods; 2016 Jan; 92():64-71. PubMed ID: 26320830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors.
    Reiter E; Ahn S; Shukla AK; Lefkowitz RJ
    Annu Rev Pharmacol Toxicol; 2012; 52():179-97. PubMed ID: 21942629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evasive nature of drug efficacy: implications for drug discovery.
    Galandrin S; Oligny-Longpré G; Bouvier M
    Trends Pharmacol Sci; 2007 Aug; 28(8):423-30. PubMed ID: 17659355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arrestins and protein ubiquitination.
    Kommaddi RP; Shenoy SK
    Prog Mol Biol Transl Sci; 2013; 118():175-204. PubMed ID: 23764054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging structural insights into biased GPCR signaling.
    Shukla AK; Singh G; Ghosh E
    Trends Biochem Sci; 2014 Dec; 39(12):594-602. PubMed ID: 25458114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.
    Shonberg J; Lopez L; Scammells PJ; Christopoulos A; Capuano B; Lane JR
    Med Res Rev; 2014 Nov; 34(6):1286-330. PubMed ID: 24796277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology.
    DeWire SM; Violin JD
    Circ Res; 2011 Jul; 109(2):205-16. PubMed ID: 21737816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying biased β-arrestin signaling.
    Kenakin T
    Handb Exp Pharmacol; 2014; 219():57-83. PubMed ID: 24292824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When simple agonism is not enough: emerging modalities of GPCR ligands.
    Smith NJ; Bennett KA; Milligan G
    Mol Cell Endocrinol; 2011 Jan; 331(2):241-7. PubMed ID: 20654693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.